{"nctId":"NCT00360334","briefTitle":"A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients","startDateStruct":{"date":"2006-06"},"conditions":["Type 2 Diabetes"],"count":235,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine"]}],"interventions":[{"name":"exenatide","otherNames":["Byetta"]},{"name":"insulin glargine","otherNames":["Lantus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes\n* Currently being treated with the following: Dual or triple oral therapy - on a stable combination and dose for at least 3 months.\n* HbA1c between 7.5% and 10.0%.\n* BMI \\>27.\n\nExclusion Criteria:\n\n* Receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to study.\n* Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.\n* Treatment with the following medications: \\*Insulin as outpatient therapy within last 3 months; \\*Meglitinides, or acarbose within the last 3 months; \\*Regular use of any drugs that directly affect gastrointestinal motility; \\*Any previous (study) therapy with exenatide or glucagon-like peptide-1 (GLP-1) analogue; \\*Anti-obesity agent use within the last 3 months.\n* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)","description":"Composite endpoint evaluating effect of treatment on glycemic control and weight","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"19.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Who Achieved HbA1c ≤ 7.4% and Weight Gain ≤ 0.5kg","description":"Composite endpoint evaluating effect of treatment on glycemic control and weight","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null},{"groupId":"OG001","value":"16.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Glucose","description":"Change in fasting serum glucose from baseline (week 0) to endpoint (week 26)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.12","spread":"0.25"},{"groupId":"OG001","value":"-3.61","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Achieving HbA1c ≤ 7.4%","description":"Percent of patients achieving specified HbA1c target at endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":null},{"groupId":"OG001","value":"61.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Achieving HbA1c < 7%","description":"Percent of patients achieving specified HbA1c target at endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"43.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Achieving HbA1c < 6.5%","description":"Percent of patients achieving specified HbA1c target at endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in 7 Point Self Monitored Blood Glucose Profile","description":"Change from baseline to endpoint in self monitored blood glucose levels measured at 7 time points during the day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.98","spread":"2.11"},{"groupId":"OG001","value":"9.88","spread":"2.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.01","spread":"2.14"},{"groupId":"OG001","value":"-3.99","spread":"2.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.53","spread":"3.07"},{"groupId":"OG001","value":"13.33","spread":"2.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.09","spread":"3.52"},{"groupId":"OG001","value":"-3.95","spread":"3.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.95","spread":"3.24"},{"groupId":"OG001","value":"9.54","spread":"2.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.21","spread":"3.11"},{"groupId":"OG001","value":"-2.59","spread":"3.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.07","spread":"3.27"},{"groupId":"OG001","value":"11.15","spread":"2.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.20","spread":"3.30"},{"groupId":"OG001","value":"-2.48","spread":"3.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.95","spread":"2.97"},{"groupId":"OG001","value":"9.37","spread":"2.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.13","spread":"2.89"},{"groupId":"OG001","value":"-1.46","spread":"4.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.59","spread":"3.28"},{"groupId":"OG001","value":"11.80","spread":"2.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.59","spread":"3.30"},{"groupId":"OG001","value":"-2.06","spread":"3.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.63","spread":"3.23"},{"groupId":"OG001","value":"11.24","spread":"3.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.56","spread":"3.19"},{"groupId":"OG001","value":"-2.20","spread":"3.47"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Change in BMI from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.49","spread":"0.49"},{"groupId":"OG001","value":"33.71","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"0.11"},{"groupId":"OG001","value":"1.01","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change in waist circumference from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112.07","spread":"1.30"},{"groupId":"OG001","value":"110.64","spread":"1.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.19","spread":"0.54"},{"groupId":"OG001","value":"1.97","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Change in Waist-to-hip Ratio","description":"Change in waist-to-hip ratio from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.01"},{"groupId":"OG001","value":"0.98","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.00"},{"groupId":"OG001","value":"0.01","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101.19","spread":"1.68"},{"groupId":"OG001","value":"97.93","spread":"1.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.73","spread":"0.31"},{"groupId":"OG001","value":"2.98","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight","description":"Percent change in baseline body weight at endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"0.3"},{"groupId":"OG001","value":"3.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Achieving 5% Weight Loss","description":"Percent of patients who lost at least 5% of baseline body weight at endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Achieving 10% Weight Loss","description":"Percent of patients who lost at least 10% of baseline body weight at endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134.0","spread":"1.5"},{"groupId":"OG001","value":"134.7","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"1.2"},{"groupId":"OG001","value":"0.6","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":"0.8"},{"groupId":"OG001","value":"79.7","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.7"},{"groupId":"OG001","value":"0.9","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Total Cholesterol (TC)","description":"Change in TC from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"0.07"},{"groupId":"OG001","value":"-0.21","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change in High Density Lipoprotein (HDL) Cholesterol","description":"Change in HDL cholesterol from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.01"},{"groupId":"OG001","value":"0.02","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Change in TC to HDL Cholesterol Ratio","description":"Change in TC to HDL cholesterol ratio from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"0.10"},{"groupId":"OG001","value":"-0.34","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Triglycerides","description":"Change in fasting serum triglycerides from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.08"},{"groupId":"OG001","value":"-0.38","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in Low Density Lipoprotein (LDL) Cholesterol","description":"Change in LDL cholesterol from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.06"},{"groupId":"OG001","value":"-0.07","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change in Apolipoprotein-B","description":"Change in apolipoprotein-B from baseline to endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.02"},{"groupId":"OG001","value":"-0.08","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Incidence of Hypoglycemic Episodes","description":"Percent of total patients in each arm experiencing hypoglycemia at any point in the 26 week study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"59.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Nocturnal Hypoglycemic Episodes","description":"Percent of total patients in each arm experiencing nocturnal hypoglycemia at any point in the 26 week study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"29.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Severe Hypoglycemic Episodes","description":"Percent of total patients in each arm experiencing severe hypoglycemia at any point during the 26 week study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Hypoglycemic Rate Per 30 Days","description":"Number of hypoglycemic episodes per patient adjusted per 30 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.069","spread":null},{"groupId":"OG001","value":"0.164","spread":null}]}]}]},{"type":"SECONDARY","title":"Nocturnal Hypoglycemic Rate Per 30 Days","description":"Number of nocturnal hypoglycemic episodes per patient adjusted per 30 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]}]},{"type":"SECONDARY","title":"Severe Hypoglycemic Rate Per 30 Days","description":"Number of severe hypoglycemic episodes per patient adjusted per 30 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5},"commonTop":["Nausea","Nasopharyngitis","Diarrhoea","Headache","Vomiting"]}}}